Literature DB >> 1320542

Increases in NO2-/NO3- excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure.

H Suzuki1, H Ikenaga, K Hishikawa, T Nakaki, R Kato, T Saruta.   

Abstract

1. Under hormonally constant conditions, the effects of a sudden increase in blood pressure on the release of endothelium-derived relaxing factor were evaluated by measuring urinary excretion of NO2-/NO3- in rats with renal denervation. 2. Elevation of blood pressure from 136 +/- 2 to 153 +/- 3 mmHg by an aortic clamp below the renal arteries induced a significant increase in urinary excretion of NO2-/NO3- from 76.6 +/- 4.2 x 10(2) to 108.1 +/- 8.3 x 10(2) pmol min-1 g-1 kidney weight (P less than 0.05). 3. Infusion of NG-monomethyl-L-arginine (1 mg min-1 kg-1) without an aortic clamp raised mean blood pressure to a similar level; however, urinary excretion of NO2-/NO3- was decreased significantly. 4. During infusion of NG-monomethyl-L-arginine, aortic occlusion caused a significant increase in blood pressure without any changes in NO2-/NO3- excretion in the urine. 5. These results suggest that the formation of NO, an indicator of endothelium-derived relaxing factor release, was increased by mechanical pressure elevation without apparent changes in hormonal and neural factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320542     DOI: 10.1042/cs0820631

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

1.  Prehypertensive African-American women have preserved nitric oxide and renal function but high cardiovascular risk.

Authors:  Deborah L Feairheller; Kathleen M Sturgeon; Keith M Diaz; Praveen Veerabhadrappa; Sheara T Williamson; Deborah L Crabbe; Michael D Brown
Journal:  Kidney Blood Press Res       Date:  2010-07-13       Impact factor: 2.687

2.  Changes in nitric oxide release in vivo in response to vasoactive substances.

Authors:  E Nava; N P Wiklund; F J Salazar
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Pharmacokinetics of intravenous and oral L-arginine in normal volunteers.

Authors:  O Tangphao; M Grossmann; S Chalon; B B Hoffman; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

4.  Increased urinary nitrate excretion in rats with adjuvant arthritis.

Authors:  D O Stichtenoth; F M Gutzki; D Tsikas; N Selve; S M Bode-Böger; R H Böger; J C Frölich
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

5.  Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone.

Authors:  D O Stichtenoth; J Fauler; H Zeidler; J C Frölich
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

6.  Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures.

Authors:  J Brice Weinberg; Thomas Lang; William E Wilkinson; David S Pisetsky; E William St Clair
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  A Single Dose of Beetroot Gel Rich in Nitrate Does Not Improve Performance but Lowers Blood Glucose in Physically Active Individuals.

Authors:  Julia Vasconcellos; Diego Henrique Silvestre; Diego Dos Santos Baião; João Pedro Werneck-de-Castro; Thiago Silveira Alvares; Vânia M Flosi Paschoalin
Journal:  J Nutr Metab       Date:  2017-01-24

8.  Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF in patients with myocardial infarction in the randomized RIMINI-Trial.

Authors:  Tjark F Schwemer; Navina Deutscher; Nadine Diermann; Rainer Böger; Edzard Schwedhelm; Stefan Blankenberg; Felix W Friedrich
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

9.  Nitric oxide function in atherosclerosis.

Authors:  K E Matthys; H Bult
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.